TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00632814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 70 IU/kg, dosing by injection twice per week (30 IU/kg \[day 1\] + 40 IU/kg \[day 4\]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
Description: rFVIII-FS (Octocog-alfa, antihemophilic factor \[recombinant\]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg \[day 1, 3, 5\]) for 9 months. No escalation opportunity for patients in this group
Study: NCT00912535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine extended release tablet
Description: Quetiapine extended release tablet of 50-300mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally, as adjunct to the same antidepressant at the same dose.
Study: NCT01152957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARIÑO Project
Description: Care Attention Resources Information Nutrition \& Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Usual care plus 4 health education brochures
Study: NCT04269668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Minimed 670G 3.0 HCL
Description: Hybrid closed loop system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Minimed 670G 4.0 AHCL
Description: Advanced hybrid closed loop system
Study: NCT01123798

Intervention type: DEVICE
Intervention: near-infrared spectroscopy
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.

Intervention type: DEVICE
Intervention: near-infrared spectroscopy
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.

Intervention type: DEVICE
Intervention: near-infrared spectroscopy
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
Study: NCT04457297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine and tipiracil
Description: Trifluridine and tipiracil will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be orally administered twice daily on Days 1 to 5 and Days 8 to 12. The administration will be repeated until completion of 6 courses(one course consists of 28 days) or until any discontinuation criterion is met.
Study: NCT02464540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminate veneers luted with light-cured resin cement
Description: After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminate veneers luted with light-cured flowable composite
Description: After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL\*a\* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
Study: NCT02817646

Intervention type: OTHER
Intervention: Computed tomography scan made for clinical reasons
Description: Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrition as per hospital protocol
Description: Patients received enteral and/or parenteral nutrition as per usual hospital protocol
Study: NCT03039218

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries 2
Description: Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Sham
Description: Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
Study: NCT02741739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Study: NCT02612779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01816035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study: NCT04146948

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study

Intervention type: OTHER
Intervention: no intervention
Description: no intervention in this study
Study: NCT01451112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured dermal and epidermal cells
Description: A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
Study: NCT01113086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial direct current stimulation
Description: Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
Study: NCT00446849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX Mesalamine
Description: MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
Study: NCT05077202

Intervention type: DEVICE
Intervention: ultra sound
Description: chest ultrasound
Study: NCT02744326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
Study: NCT02888704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSTEM Inj. (Adult human mesenchymal stem cells)
Description: Comparison of different dosages of the drug in the aspect of safety and efficacy.
Study: NCT01640054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 100mg once daily
Study: NCT02301598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)
Description: The procedure was a non-penetrating transplantation of 80% thickness corneal graft
Study: NCT03022032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Zip
Description: Fitbit Zip

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOPE App
Description: HOPE App

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOPE App
Description: HOPE App

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOPE App
Description: HOPE App

Intervention type: OTHER
Group type: OTHER
Intervention: HOPE App
Description: HOPE App

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOPE App
Description: HOPE App

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 2
Description: Fitbit Charge 2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 2
Description: Fitbit Charge 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART Study Intervention
Description: SMART study app + Beiwe study app + Fitbit
Study: NCT00260663

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group hearing aid fittings

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group hearing aid follow-up
Study: NCT02650245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAS Myoplex Protein Drink + 10gm lactulose
Study: NCT01652599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag and dexamethasone
Description: Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
Study: NCT02080221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXA
Study: NCT03089151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Garden Intervention
Description: The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year.
Study: NCT01280812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based physical activity intervention with maintenance plus
Description: This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based physical activity intervention with maintenance regular
Description: This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (pedometer only)
Description: This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
Study: NCT01385878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Phacoemulsification through small clear corneal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Phacoemulsification through small clear corneal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Phacoemulsification through clear corneal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Phacoemulsification through clear corneal incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Microcoaxial Phacoemulsification through 1.8mm incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Microcoaxial Phacoemulsification through 1.8mm incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microcoaxial Phacoemulsification
Description: Microcoaxial phacoemulsification through 2.2mm incision
Study: NCT02536391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib (tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.
Study: NCT02883283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural loading dose
Description: Labor epidural analgesia loading dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural loading dose
Description: Labor epidural analgesia loading dose

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: Epidural loading dose via epidural catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural needle
Description: Epidural loading dose via epidural needle
Study: NCT02584582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liquid meal test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal test

Intervention type: OTHER
Group type: OTHER
Intervention: No drug (Baseline day)
Study: NCT02985320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of high dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of medium dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of low dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of low dosage investigational sIPV
Description: The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized sIPV
Description: The control vaccine was manufactured by Chinese Academy of Medical Sciences.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three-dose regimen of commercialized IPV
Description: The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
Study: NCT02972866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Study: NCT00738582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009 (Amatuximab)
Description: MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Study: NCT02416817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Products only
Description: Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care guided
Description: Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
Study: NCT03718533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
Study: NCT03728322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iHSCs treatment group
Description: iHSCs intravenous injection
Study: NCT02312388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: catheter-over-the-needle technique
Description: using a 22 G Angiocath Plus™ catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin-wall needle technique
Description: using 18 - 21 G introducer needle